Novel peptide-based oncolytic vaccine for enhancement of adaptive antitumor immune response via co-engagement of innate Fcγ and Fcα receptors.

Autor: Feola S; University of Helsinki Faculty of Pharmacy, Laboratory of Immunovirotherapy, Drug Research Program Helsinki, Uusimaa, FI, Helsinki, Finland.; Helsinki Institute of Life Science (HiLIFE), Fabianinkatu 33, University of Helsinki, 00710 Helsinki, Finland, Helsinki, Finland.; Translational Immunology Program (TRIMM), Faculty of Medicine Helsinki University, Helsinki, Finland.; Digital Precision Cancer Medicine Flagship (iCAN), University of Helsinki, Helsinki, Finland., Hamdan F; University of Helsinki Faculty of Pharmacy, Laboratory of Immunovirotherapy, Drug Research Program Helsinki, Uusimaa, FI, Helsinki, Finland.; Helsinki Institute of Life Science (HiLIFE), Fabianinkatu 33, University of Helsinki, 00710 Helsinki, Finland, Helsinki, Finland.; Translational Immunology Program (TRIMM), Faculty of Medicine Helsinki University, Helsinki, Finland.; Digital Precision Cancer Medicine Flagship (iCAN), University of Helsinki, Helsinki, Finland., Russo S; University of Helsinki Faculty of Pharmacy, Laboratory of Immunovirotherapy, Drug Research Program Helsinki, Uusimaa, FI, Helsinki, Finland.; Helsinki Institute of Life Science (HiLIFE), Fabianinkatu 33, University of Helsinki, 00710 Helsinki, Finland, Helsinki, Finland.; Translational Immunology Program (TRIMM), Faculty of Medicine Helsinki University, Helsinki, Finland.; Digital Precision Cancer Medicine Flagship (iCAN), University of Helsinki, Helsinki, Finland., Chiaro J; University of Helsinki Faculty of Pharmacy, Laboratory of Immunovirotherapy, Drug Research Program Helsinki, Uusimaa, FI, Helsinki, Finland.; Helsinki Institute of Life Science (HiLIFE), Fabianinkatu 33, University of Helsinki, 00710 Helsinki, Finland, Helsinki, Finland.; Translational Immunology Program (TRIMM), Faculty of Medicine Helsinki University, Helsinki, Finland.; Digital Precision Cancer Medicine Flagship (iCAN), University of Helsinki, Helsinki, Finland., Fusciello M; University of Helsinki Faculty of Pharmacy, Laboratory of Immunovirotherapy, Drug Research Program Helsinki, Uusimaa, FI, Helsinki, Finland.; Helsinki Institute of Life Science (HiLIFE), Fabianinkatu 33, University of Helsinki, 00710 Helsinki, Finland, Helsinki, Finland.; Translational Immunology Program (TRIMM), Faculty of Medicine Helsinki University, Helsinki, Finland.; Digital Precision Cancer Medicine Flagship (iCAN), University of Helsinki, Helsinki, Finland., Feodoroff M; University of Helsinki Faculty of Pharmacy, Laboratory of Immunovirotherapy, Drug Research Program Helsinki, Uusimaa, FI, Helsinki, Finland.; Helsinki Institute of Life Science (HiLIFE), Fabianinkatu 33, University of Helsinki, 00710 Helsinki, Finland, Helsinki, Finland.; Translational Immunology Program (TRIMM), Faculty of Medicine Helsinki University, Helsinki, Finland.; Digital Precision Cancer Medicine Flagship (iCAN), University of Helsinki, Helsinki, Finland., Antignani G; University of Helsinki Faculty of Pharmacy, Laboratory of Immunovirotherapy, Drug Research Program Helsinki, Uusimaa, FI, Helsinki, Finland.; Helsinki Institute of Life Science (HiLIFE), Fabianinkatu 33, University of Helsinki, 00710 Helsinki, Finland, Helsinki, Finland.; Translational Immunology Program (TRIMM), Faculty of Medicine Helsinki University, Helsinki, Finland.; Digital Precision Cancer Medicine Flagship (iCAN), University of Helsinki, Helsinki, Finland., D'Alessio F; University of Helsinki Faculty of Pharmacy, Laboratory of Immunovirotherapy, Drug Research Program Helsinki, Uusimaa, FI, Helsinki, Finland.; Helsinki Institute of Life Science (HiLIFE), Fabianinkatu 33, University of Helsinki, 00710 Helsinki, Finland, Helsinki, Finland.; Translational Immunology Program (TRIMM), Faculty of Medicine Helsinki University, Helsinki, Finland.; Digital Precision Cancer Medicine Flagship (iCAN), University of Helsinki, Helsinki, Finland., Mölsä R; University of Helsinki Faculty of Pharmacy, Laboratory of Immunovirotherapy, Drug Research Program Helsinki, Uusimaa, FI, Helsinki, Finland.; Helsinki Institute of Life Science (HiLIFE), Fabianinkatu 33, University of Helsinki, 00710 Helsinki, Finland, Helsinki, Finland.; Translational Immunology Program (TRIMM), Faculty of Medicine Helsinki University, Helsinki, Finland.; Digital Precision Cancer Medicine Flagship (iCAN), University of Helsinki, Helsinki, Finland., Stigzelius V; University of Helsinki Faculty of Pharmacy, Laboratory of Immunovirotherapy, Drug Research Program Helsinki, Uusimaa, FI, Helsinki, Finland.; Helsinki Institute of Life Science (HiLIFE), Fabianinkatu 33, University of Helsinki, 00710 Helsinki, Finland, Helsinki, Finland.; Translational Immunology Program (TRIMM), Faculty of Medicine Helsinki University, Helsinki, Finland.; Digital Precision Cancer Medicine Flagship (iCAN), University of Helsinki, Helsinki, Finland., Bottega P; University of Helsinki Faculty of Pharmacy, Laboratory of Immunovirotherapy, Drug Research Program Helsinki, Uusimaa, FI, Helsinki, Finland.; Helsinki Institute of Life Science (HiLIFE), Fabianinkatu 33, University of Helsinki, 00710 Helsinki, Finland, Helsinki, Finland.; Translational Immunology Program (TRIMM), Faculty of Medicine Helsinki University, Helsinki, Finland.; Digital Precision Cancer Medicine Flagship (iCAN), University of Helsinki, Helsinki, Finland., Pesonen S; Valo Therapeutics Oy, Helsinki, Finland., Leusen J; Center for translational immunology, UMC Utrecht, Utrecht, The Netherlands., Grönholm M; University of Helsinki Faculty of Pharmacy, Laboratory of Immunovirotherapy, Drug Research Program Helsinki, Uusimaa, FI, Helsinki, Finland.; Helsinki Institute of Life Science (HiLIFE), Fabianinkatu 33, University of Helsinki, 00710 Helsinki, Finland, Helsinki, Finland.; Translational Immunology Program (TRIMM), Faculty of Medicine Helsinki University, Helsinki, Finland.; Digital Precision Cancer Medicine Flagship (iCAN), University of Helsinki, Helsinki, Finland., Cerullo V; University of Helsinki Faculty of Pharmacy, Laboratory of Immunovirotherapy, Drug Research Program Helsinki, Uusimaa, FI, Helsinki, Finland vincenzo.cerullo@helsinki.fi.; Helsinki Institute of Life Science (HiLIFE), Fabianinkatu 33, University of Helsinki, 00710 Helsinki, Finland, Helsinki, Finland.; Translational Immunology Program (TRIMM), Faculty of Medicine Helsinki University, Helsinki, Finland.; Digital Precision Cancer Medicine Flagship (iCAN), University of Helsinki, Helsinki, Finland.; Department of Molecular Medicine and Medical Biotechnology and CEINGE, Naples University Federico II, Naples, Italy.

Publikováno v: Journal for immunotherapy of cancer [J Immunother Cancer] 2024 Mar 08; Vol. 12 (3). Date of Electronic Publication: 2024 Mar 08.

Development of mesothelioma-specific oncolytic immunotherapy enabled by immunopeptidomics of murine and human mesothelioma tumors.

Autor: Chiaro J; Drug Research Program (DRP), ImmunoViroTherapy Lab (IVT), Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Viikinkaari 5E, 00790, Helsinki, Finland.; Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Fabianinkatu 33, 00710, Helsinki, Finland.; Translational Immunology Program (TRIMM), Faculty of Medicine Helsinki University, University of Helsinki, Haartmaninkatu 8, 00290, Helsinki, Finland.; Digital Precision Cancer Medicine Flagship (iCAN), University of Helsinki, 00014, Helsinki, Finland., Antignani G; Drug Research Program (DRP), ImmunoViroTherapy Lab (IVT), Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Viikinkaari 5E, 00790, Helsinki, Finland.; Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Fabianinkatu 33, 00710, Helsinki, Finland.; Translational Immunology Program (TRIMM), Faculty of Medicine Helsinki University, University of Helsinki, Haartmaninkatu 8, 00290, Helsinki, Finland.; Digital Precision Cancer Medicine Flagship (iCAN), University of Helsinki, 00014, Helsinki, Finland., Feola S; Drug Research Program (DRP), ImmunoViroTherapy Lab (IVT), Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Viikinkaari 5E, 00790, Helsinki, Finland.; Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Fabianinkatu 33, 00710, Helsinki, Finland.; Translational Immunology Program (TRIMM), Faculty of Medicine Helsinki University, University of Helsinki, Haartmaninkatu 8, 00290, Helsinki, Finland.; Digital Precision Cancer Medicine Flagship (iCAN), University of Helsinki, 00014, Helsinki, Finland., Feodoroff M; Drug Research Program (DRP), ImmunoViroTherapy Lab (IVT), Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Viikinkaari 5E, 00790, Helsinki, Finland.; Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Fabianinkatu 33, 00710, Helsinki, Finland.; Translational Immunology Program (TRIMM), Faculty of Medicine Helsinki University, University of Helsinki, Haartmaninkatu 8, 00290, Helsinki, Finland.; Digital Precision Cancer Medicine Flagship (iCAN), University of Helsinki, 00014, Helsinki, Finland.; Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland., Martins B; Drug Research Program (DRP), ImmunoViroTherapy Lab (IVT), Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Viikinkaari 5E, 00790, Helsinki, Finland.; Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Fabianinkatu 33, 00710, Helsinki, Finland.; Translational Immunology Program (TRIMM), Faculty of Medicine Helsinki University, University of Helsinki, Haartmaninkatu 8, 00290, Helsinki, Finland.; Digital Precision Cancer Medicine Flagship (iCAN), University of Helsinki, 00014, Helsinki, Finland., Cojoc H; Valo Therapeutics Oy, Viikinkaari 6, Helsinki, Finland, 00790, Helsinki, Finland., Russo S; Drug Research Program (DRP), ImmunoViroTherapy Lab (IVT), Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Viikinkaari 5E, 00790, Helsinki, Finland.; Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Fabianinkatu 33, 00710, Helsinki, Finland.; Translational Immunology Program (TRIMM), Faculty of Medicine Helsinki University, University of Helsinki, Haartmaninkatu 8, 00290, Helsinki, Finland.; Digital Precision Cancer Medicine Flagship (iCAN), University of Helsinki, 00014, Helsinki, Finland., Fusciello M; Drug Research Program (DRP), ImmunoViroTherapy Lab (IVT), Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Viikinkaari 5E, 00790, Helsinki, Finland.; Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Fabianinkatu 33, 00710, Helsinki, Finland.; Translational Immunology Program (TRIMM), Faculty of Medicine Helsinki University, University of Helsinki, Haartmaninkatu 8, 00290, Helsinki, Finland.; Digital Precision Cancer Medicine Flagship (iCAN), University of Helsinki, 00014, Helsinki, Finland., Hamdan F; Drug Research Program (DRP), ImmunoViroTherapy Lab (IVT), Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Viikinkaari 5E, 00790, Helsinki, Finland.; Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Fabianinkatu 33, 00710, Helsinki, Finland.; Translational Immunology Program (TRIMM), Faculty of Medicine Helsinki University, University of Helsinki, Haartmaninkatu 8, 00290, Helsinki, Finland.; Digital Precision Cancer Medicine Flagship (iCAN), University of Helsinki, 00014, Helsinki, Finland., Ferrari V; Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, 20090, Pieve Emanuele, MI, Italy., Ciampi D; Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, 20090, Pieve Emanuele, MI, Italy., Ilonen I; Department of General Thoracic and Esophageal Surgery, Heart and Lung Center, Helsinki University Hospital, 00029, Helsinki, Finland.; Department of Surgery, Clinicum, University of Helsinki, 00029, Helsinki, Finland., Räsänen J; Department of General Thoracic and Esophageal Surgery, Heart and Lung Center, Helsinki University Hospital, 00029, Helsinki, Finland.; Department of Surgery, Clinicum, University of Helsinki, 00029, Helsinki, Finland., Mäyränpää M; Department of Pathology, Helsinki University Hospital, Helsinki, Finland., Partanen J; Research & Development Finnish Red Cross Blood Service Helsinki, Kivihaantie 7, 00310, Helsinki, Finland., Koskela S; Finnish Red Cross Blood Service Biobank, Härkälenkki 13, 01730, Vantaa, Finland., Honkanen J; Finnish Red Cross Blood Service Biobank, Härkälenkki 13, 01730, Vantaa, Finland., Halonen J; Finnish Red Cross Blood Service Biobank, Härkälenkki 13, 01730, Vantaa, Finland., Kuryk L; Valo Therapeutics Oy, Viikinkaari 6, Helsinki, Finland, 00790, Helsinki, Finland.; Department of Virology, National Institute of Public Health NIH-National Research Institute, 24 Chocimska Str., 00-791, Warsaw, Poland., Rescigno M; Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, 20090, Pieve Emanuele, MI, Italy.; IRCCS Humanitas Research Hospital, Via Manzoni 56, 20089, Rozzano, MI, Italy., Grönholm M; Drug Research Program (DRP), ImmunoViroTherapy Lab (IVT), Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Viikinkaari 5E, 00790, Helsinki, Finland.; Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Fabianinkatu 33, 00710, Helsinki, Finland.; Translational Immunology Program (TRIMM), Faculty of Medicine Helsinki University, University of Helsinki, Haartmaninkatu 8, 00290, Helsinki, Finland.; Digital Precision Cancer Medicine Flagship (iCAN), University of Helsinki, 00014, Helsinki, Finland., Branca RM; Science for Life Laboratory, Department of Oncology-Pathology, Karolinska Institutet, Solna, Sweden., Lehtiö J; Science for Life Laboratory, Department of Oncology-Pathology, Karolinska Institutet, Solna, Sweden., Cerullo V; Drug Research Program (DRP), ImmunoViroTherapy Lab (IVT), Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Viikinkaari 5E, 00790, Helsinki, Finland. vincenzo.cerullo@helsinki.fi.; Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Fabianinkatu 33, 00710, Helsinki, Finland. vincenzo.cerullo@helsinki.fi.; Translational Immunology Program (TRIMM), Faculty of Medicine Helsinki University, University of Helsinki, Haartmaninkatu 8, 00290, Helsinki, Finland. vincenzo.cerullo@helsinki.fi.; Digital Precision Cancer Medicine Flagship (iCAN), University of Helsinki, 00014, Helsinki, Finland. vincenzo.cerullo@helsinki.fi.; Department of Molecular Medicine and Medical Biotechnology and CEINGE, Naples University Federico II, 80131, Naples, Italy. vincenzo.cerullo@helsinki.fi.

Publikováno v: Nature communications [Nat Commun] 2023 Nov 03; Vol. 14 (1), pp. 7056. Date of Electronic Publication: 2023 Nov 03.

A novel immunopeptidomic-based pipeline for the generation of personalized oncolytic cancer vaccines

Autor: Manlio Fusciello, Firas Hamdan, Janne Lehtiö, Feodoroff M, Jacopo Chiaro, S. Pesonen, Antignani G, Cerullo, Beatriz Martins, Branca Rmm, Sara Feola, Tapani Viitala, Russo S, Erkko Ylösmäki, Gronholm M

Beside the isolation and identification of MHC-I restricted peptides from the surface of cancer cells, one of the challenges is eliciting an effective anti-tumor CD8+ T cell mediated response as part of therapeutic cancer vaccine. Therefore, the esta

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::bf3d1f895fed60541cd61d94ca53a5e7
https://doi.org/10.1101/2021.06.08.447483

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

A novel immunopeptidomic-based pipeline for the generation of personalized oncolytic cancer vaccines.

Autor: Feola S; Drug Research Program (DRP) ImmunoViroTherapy Lab (IVT), Division of Pharmaceutical Biosciences, Faculty of Pharmacy, Viikinkaari 5E, University of Helsinki, Helsinki, Finland.; Helsinki Institute of Life Science (HiLIFE), Fabianinkatu 33, University of Helsinki, Helsinki, Finland.; Translational Immunology Program (TRIMM), Faculty of Medicine Helsinki University, postal code Haartmaninkatu 8, University of Helsinki, Helsinki, Finland., Chiaro J; Drug Research Program (DRP) ImmunoViroTherapy Lab (IVT), Division of Pharmaceutical Biosciences, Faculty of Pharmacy, Viikinkaari 5E, University of Helsinki, Helsinki, Finland.; Helsinki Institute of Life Science (HiLIFE), Fabianinkatu 33, University of Helsinki, Helsinki, Finland.; Translational Immunology Program (TRIMM), Faculty of Medicine Helsinki University, postal code Haartmaninkatu 8, University of Helsinki, Helsinki, Finland., Martins B; Drug Research Program (DRP) ImmunoViroTherapy Lab (IVT), Division of Pharmaceutical Biosciences, Faculty of Pharmacy, Viikinkaari 5E, University of Helsinki, Helsinki, Finland.; Helsinki Institute of Life Science (HiLIFE), Fabianinkatu 33, University of Helsinki, Helsinki, Finland.; Translational Immunology Program (TRIMM), Faculty of Medicine Helsinki University, postal code Haartmaninkatu 8, University of Helsinki, Helsinki, Finland., Russo S; Drug Research Program (DRP) ImmunoViroTherapy Lab (IVT), Division of Pharmaceutical Biosciences, Faculty of Pharmacy, Viikinkaari 5E, University of Helsinki, Helsinki, Finland.; Helsinki Institute of Life Science (HiLIFE), Fabianinkatu 33, University of Helsinki, Helsinki, Finland.; Translational Immunology Program (TRIMM), Faculty of Medicine Helsinki University, postal code Haartmaninkatu 8, University of Helsinki, Helsinki, Finland., Fusciello M; Drug Research Program (DRP) ImmunoViroTherapy Lab (IVT), Division of Pharmaceutical Biosciences, Faculty of Pharmacy, Viikinkaari 5E, University of Helsinki, Helsinki, Finland.; Helsinki Institute of Life Science (HiLIFE), Fabianinkatu 33, University of Helsinki, Helsinki, Finland.; Translational Immunology Program (TRIMM), Faculty of Medicine Helsinki University, postal code Haartmaninkatu 8, University of Helsinki, Helsinki, Finland., Ylösmäki E; Drug Research Program (DRP) ImmunoViroTherapy Lab (IVT), Division of Pharmaceutical Biosciences, Faculty of Pharmacy, Viikinkaari 5E, University of Helsinki, Helsinki, Finland.; Helsinki Institute of Life Science (HiLIFE), Fabianinkatu 33, University of Helsinki, Helsinki, Finland.; Translational Immunology Program (TRIMM), Faculty of Medicine Helsinki University, postal code Haartmaninkatu 8, University of Helsinki, Helsinki, Finland., Bonini C; Experimental Hematology Unit, Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute, University Vita-Salute San Raffaele, Milan, Italy., Ruggiero E; Experimental Hematology Unit, Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute, University Vita-Salute San Raffaele, Milan, Italy., Hamdan F; Drug Research Program (DRP) ImmunoViroTherapy Lab (IVT), Division of Pharmaceutical Biosciences, Faculty of Pharmacy, Viikinkaari 5E, University of Helsinki, Helsinki, Finland.; Helsinki Institute of Life Science (HiLIFE), Fabianinkatu 33, University of Helsinki, Helsinki, Finland.; Translational Immunology Program (TRIMM), Faculty of Medicine Helsinki University, postal code Haartmaninkatu 8, University of Helsinki, Helsinki, Finland., Feodoroff M; Drug Research Program (DRP) ImmunoViroTherapy Lab (IVT), Division of Pharmaceutical Biosciences, Faculty of Pharmacy, Viikinkaari 5E, University of Helsinki, Helsinki, Finland.; Helsinki Institute of Life Science (HiLIFE), Fabianinkatu 33, University of Helsinki, Helsinki, Finland.; Translational Immunology Program (TRIMM), Faculty of Medicine Helsinki University, postal code Haartmaninkatu 8, University of Helsinki, Helsinki, Finland.; Digital Precision Cancer Medicine Flagship (iCAN), University of Helsinki, Helsinki, Finland.; Institute for Molecular Medicine Finland, FIMM, Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Helsinki, Finland., Antignani G; Drug Research Program (DRP) ImmunoViroTherapy Lab (IVT), Division of Pharmaceutical Biosciences, Faculty of Pharmacy, Viikinkaari 5E, University of Helsinki, Helsinki, Finland.; Helsinki Institute of Life Science (HiLIFE), Fabianinkatu 33, University of Helsinki, Helsinki, Finland.; Translational Immunology Program (TRIMM), Faculty of Medicine Helsinki University, postal code Haartmaninkatu 8, University of Helsinki, Helsinki, Finland., Viitala T; Pharmaceutical Biophysics Research Group, Drug Research Program, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland., Pesonen S; Valo Therapeutics Oy, Helsinki, Finland., Grönholm M; Drug Research Program (DRP) ImmunoViroTherapy Lab (IVT), Division of Pharmaceutical Biosciences, Faculty of Pharmacy, Viikinkaari 5E, University of Helsinki, Helsinki, Finland.; Helsinki Institute of Life Science (HiLIFE), Fabianinkatu 33, University of Helsinki, Helsinki, Finland.; Translational Immunology Program (TRIMM), Faculty of Medicine Helsinki University, postal code Haartmaninkatu 8, University of Helsinki, Helsinki, Finland.; Digital Precision Cancer Medicine Flagship (iCAN), University of Helsinki, Helsinki, Finland., Branca RMM; Science for Life Laboratory, Department of Oncology-Pathology, Karolinska Institutet, Solna, Sweden., Lehtiö J; Science for Life Laboratory, Department of Oncology-Pathology, Karolinska Institutet, Solna, Sweden., Cerullo V; Drug Research Program (DRP) ImmunoViroTherapy Lab (IVT), Division of Pharmaceutical Biosciences, Faculty of Pharmacy, Viikinkaari 5E, University of Helsinki, Helsinki, Finland.; Helsinki Institute of Life Science (HiLIFE), Fabianinkatu 33, University of Helsinki, Helsinki, Finland.; Translational Immunology Program (TRIMM), Faculty of Medicine Helsinki University, postal code Haartmaninkatu 8, University of Helsinki, Helsinki, Finland.; Digital Precision Cancer Medicine Flagship (iCAN), University of Helsinki, Helsinki, Finland.; Science for Life Laboratory, Department of Oncology-Pathology, Karolinska Institutet, Solna, Sweden.; Department of Molecular Medicine and Medical Biotechnology, Naples University 'Federico II', Pansini, Italy.

Publikováno v: ELife [Elife] 2022 Mar 22; Vol. 11. Date of Electronic Publication: 2022 Mar 22.